down arrow

Corvus Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2210151005
USD
8.81
0.76 (9.44%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.408.90

52 Week

2.549.30
Valuation
Technical
Day's Volume

CASH

1.23 M

Shareholding (Mar 2025)

FII

2.94%

Held by 28 FIIs

DII

67.1%

Held by 10 DIIs

Promoter

24.18%

How big is Corvus Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Corvus Pharmaceuticals, Inc. has a market capitalization of 303.83 million, with net sales of 0.00 million and a net profit of -41.40 million over the last four quarters. The company reported shareholder's funds of 32.57 million and total assets of 68.91 million as of Dec 24.

Market Cap: As of Jun 18, Corvus Pharmaceuticals, Inc. has a market capitalization of 303.83 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Corvus Pharmaceuticals reported net sales of 0.00 million and a net profit of -41.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 32.57 million and total assets of 68.91 million.

Read More

What does Corvus Pharmaceuticals, Inc. do?

22-Jun-2025

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. As of March 2025, it has a market cap of $303.83 million and reported a net profit of $15 million.

Overview:<BR>Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapies within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: 15 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 303.83 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.89<BR>- Return on Equity: -67.21%<BR>- Price to Book: 6.16<BR><BR>Contact Details:<BR>- Address: 863 Mitten Rd Ste 102, BURLINGAME CA: 94010-1311<BR>- Tel: ['1 650 9004520', '1 650 9004522']<BR>- Fax: 1 302 6555049<BR>- Website: http://www.corvuspharma.com/

Read More

Who are in the management team of Corvus Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Corvus Pharmaceuticals, Inc. includes Mr. Richard Miller (Chairman, President, and CEO) and Dr. Edith Mitchell (Director), along with Independent Directors Mr. Ian Clark, Mr. Elisha Gould, Dr. Linda Grais, and Mr. Steve Krognes.

As of March 2022, the management team of Corvus Pharmaceuticals, Inc. includes Mr. Richard Miller, who serves as the Chairman of the Board, President, and Chief Executive Officer. The Board of Directors also features Dr. Edith Mitchell as a Director, along with several Independent Directors: Mr. Ian Clark, Mr. Elisha Gould, Dr. Linda Grais, and Mr. Steve Krognes. <BR><BR>In summary, as of March 2022, the key members of the management team at Corvus Pharmaceuticals, Inc. are Mr. Richard Miller, Dr. Edith Mitchell, and several Independent Directors including Mr. Ian Clark, Mr. Elisha Gould, Dr. Linda Grais, and Mr. Steve Krognes.

Read More

Is Corvus Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Corvus Pharmaceuticals shows a bullish trend with strong momentum indicators, having outperformed the S&P 500 recently, although some longer-term metrics indicate caution.

As of 12 September 2025, the technical trend for Corvus Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly MACD and KST are mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. <BR><BR>In terms of performance, Corvus Pharmaceuticals has outperformed the S&P 500 over the past month with a return of 15.04% compared to the S&P's 2.33%, and it has a substantial 3-year return of 563.49% versus the S&P's 70.41%. Overall, the current technical stance is bullish with strong momentum indicators, although some longer-term metrics show mixed signals.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 440 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-46.22%

stock-summary
Price to Book

5.48

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
56.76%
0%
56.76%
6 Months
113.83%
0%
113.83%
1 Year
6.4%
0%
6.4%
2 Years
447.2%
0%
447.2%
3 Years
763.73%
0%
763.73%
4 Years
184.19%
0%
184.19%
5 Years
124.17%
0%
124.17%

Corvus Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Corvus Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Corvus Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly MACD and KST are mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. In terms of performance, Corvus Pharmaceuticals has outperformed the S&P 500 over the past month with a return of 15.04% compared to the S&P's 2.33%, and it has a substantial 3-year return of 563.49% versus the S&P's 70.41%. Overall, the current technical stance is bullish with strong momentum indicators, although some longer-term metrics show mixed signals....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
4.46%
EBIT to Interest (avg)
-46.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.89
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
61.76%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.11
EV to EBIT
-8.25
EV to EBITDA
-8.27
EV to Capital Employed
47.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-574.69%
ROE (Latest)
-67.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 10 Schemes (5.79%)

Foreign Institutions

Held by 28 Foreign Institutions (2.94%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -86.05% vs 33.85% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.20",
          "val2": "-5.90",
          "chgp": "-72.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.00",
          "val2": "1.80",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.00",
          "val2": "-4.30",
          "chgp": "-86.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -130.74% vs 34.62% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.50",
          "val2": "-23.30",
          "chgp": "-18.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-33.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.30",
          "val2": "-27.00",
          "chgp": "-130.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.20
-5.90
-72.88%
Interest
0.00
0.00
Exceptional Items
2.00
1.80
11.11%
Consolidate Net Profit
-8.00
-4.30
-86.05%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -86.05% vs 33.85% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.50
-23.30
-18.03%
Interest
0.00
0.00
Exceptional Items
-33.40
0.00
Consolidate Net Profit
-62.30
-27.00
-130.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -130.74% vs 34.62% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Corvus Pharmaceuticals, Inc. stock-summary
stock-summary
Corvus Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
Company Coordinates stock-summary
Company Details
863 Mitten Rd Ste 102 , BURLINGAME CA : 94010-1311
stock-summary
Tel: 1 650 90045201 650 9004522
stock-summary
http://www.corvuspharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."